NCT06977347View on ClinicalTrials.gov

Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea

NANot yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

February 1, 2027

Conditions
Severe Community-acquired Pneumonia (sCAP)
Interventions
DRUG

Piperacillin/Tazobactam

Piperacillin/tazobactam: 4.5g IV q6h (over 3h)

DRUG

Piperacillin/tazobactam + Levofloxacin

"Piperacillin/tazobactam: 4.5g IV q6h (over 3h)~\+ Levofloxacin 750mg IV q24h (over 30min)"

Trial Locations (1)

04761

Hanyang University Seoul Hospital, Seoul

All Listed Sponsors
lead

CHOSEOK YOON

OTHER

NCT06977347 - Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea | Biotech Hunter | Biotech Hunter